Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced or Metastatic Solid Tumors 2

Interventions

Specimen Handling 146pembrolizumab 120Magnetic Resonance Spectroscopy 117Cyclophosphamide 114Biopsy 97fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46venetoclax 41Radiotherapy 41Paclitaxel 40Cetuximab 40fludarabine phosphate 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 33Oxaliplatin 27Leucovorin 27Dexamethasone 27durvalumab 26X-Rays 25Irinotecan 25Radiation 24Cytarabine 24Azacitidine 24Injections 22Temozolomide 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × envafolimab × 90 days × Clear all
NCT06074497 2026-04-29

This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.

Kangabio AUSTRALIA LTD PTY

Phase 1 Active not recruiting
54 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT07260305 2026-04-24

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Kangabio AUSTRALIA LTD PTY

Phase 1 Recruiting
57 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡